Author

C. Herate

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:non-human primate· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Approach:statistical model· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

R. Marlin· 4 shared R. Le Grand· 3 shared A. Farina· 2 shared C. Fenwick· 2 shared c. raclot· 2 shared C. S.-Y. Foo· 2 shared D. Trono· 2 shared F. Donati· 2 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

R. Marlin

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ACE2 mimetic antibody potently neutralizes all SARS-CoV-2 variants and fully protects in XBB.1.5 challenged monkeys

C. Fenwick, P. Turelli, Y. Duhoo, K. Lau, C. Herate, R. Marlin, M. Lamrayah, J. Campos, L. Leuenberger, A. Farina, c. raclot, V. Genet, F. Fiscalini, J. Cesborn, L. Perez, , G. Pantaleo

bioRxiv · Jul 18, 2023 · PreprintMicrobiology

Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model

C. Herate, R. Marlin, F. Touret, N. D. Bosquet, F. Donati, F. Relouzat, L. Junges, M. Galhaut, O. Dehan, Q. Sconosciutti, A. Nougairede, X. de Lamballerie, S. van der Werf, R. Le Grand

This study shows Sotrovimab remains effective against SARS-CoV-2 BQ.1.1 in a non-human primate model, as measured by reduced viral replication.

bioRxiv · Feb 15, 2023Pathology

Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates.

A. Marc, R. Marlin, F. Donati, M. Prague, M. Kerioui, C. Herate, M. Alexandre, N. Dereuddre-bosquet, J. Bertrand, V. Contreras, S. Behillil, P. Maisonnasse, S. Van Der Werf, R. Le Grand, J. Guedj

This study examines how SARS-CoV-2 variants of concern affect viral dynamics in non-human primates, finding that most variants escape immune responses, with delta and omicron showing significant differences in viral production rates.

bioRxiv · Nov 9, 2022Microbiology

SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding properties

C. Fenwick, P. Turelli, D. Ni, L. Perez, K. Lau, E. Lana, C. Pellaton, C. Raclot, L. Esteves-Leuenberger, J. Campos, A. Farina, F. Fiscalini, C. Herate, R. Marlin, R. Abdelnabi, , G. Pantaleo

This paper identifies a potent human monoclonal antibody, P2G3, that neutralizes multiple SARS-CoV-2 variants including Omicron, and demonstrates its protective efficacy in a monkey model.

bioRxiv · Mar 18, 2022 · PreprintImmunology